Generic drug group sues FDA as controversy over LLY's weight loss drug shortage escalates
AInvestMonday, Oct 7, 2024 11:30 pm ET
1min read
LLY --

A group representing companies that produce generic versions of Eli Lilly's (LLY.US) weight loss drug, the Outsourcing Facilities Association, has filed a lawsuit against the U.S. Food and Drug Administration (FDA) in a federal court in Texas, alleging that the FDA's decision to remove the drug from the list of drugs in shortage was "arbitrary, capricious and unlawful." The plaintiffs argue that the FDA's decision deprived patients of access to important medications and are seeking a court order to vacate or modify the FDA's decision.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.